Department of Pathology, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Hum Pathol. 2019 Feb;84:254-261. doi: 10.1016/j.humpath.2018.10.007. Epub 2018 Oct 22.
Choriocarcinoma can be difficult to differentiate from other subtypes of testicular germ cell tumor and can occur unexpectedly in a distant, late metastasis. The aim of this investigation was to identify a marker superior to β-human chorionic gonadotropin (β-hCG) for choriocarcinoma. Sixty-two primary and metastatic testicular germ cell tumors (27 choriocarcinomas, 19 yolk sac tumors, 29 embryonal carcinomas, 28 seminomas, 22 teratomas, 3 epithelioid trophoblastic tumors [ETTs]) were analyzed for immunohistochemical expression of cytokeratin 7 (CK7), inhibin, p63, and β-hCG. All choriocarcinomas and ETTs were strongly positive for CK7, whereas seminomas were negative and 52% of embryonal carcinomas had weak reactivity. Eighty-four percent of yolk sac tumors and 59% of teratomas were CK7 positive. Eighty-nine percent of choriocarcinomas and 100% of ETTs were positive for inhibin, with reactivity highlighting syncytiotrophoblasts, whereas seminomas, embryonal carcinomas, yolk sac tumors, and teratomas were negative. Eighty-five percent of choriocarcinomas expressed p63, with staining mostly in mononucleated trophoblasts, whereas seminomas, embryonal carcinomas, and yolk sac tumors were negative. Teratomas expressed p63 in 32% of cases. β-hCG was reactive in 96% of choriocarcinomas, 33% of ETTs, 46% of seminomas, 54% of embryonal carcinomas, 47% of yolk sac tumors, and 32% of teratomas. β-hCG staining within other subtypes was more likely if choriocarcinoma was present elsewhere in the tumor (P = .0002). CK7 is a highly sensitive marker for choriocarcinoma and differentiates choriocarcinoma from seminoma and embryonal carcinoma. Inhibin and p63 are sensitive and specific for choriocarcinoma versus seminoma, embryonal carcinoma, and yolk sac tumor. To identify choriocarcinoma, CK7, inhibin, and p63 are superior to β-hCG.
绒癌较难与其他睾丸生殖细胞肿瘤亚型区分,且可能在远处的晚期转移中意外出现。本研究旨在寻找一种优于β-人绒毛膜促性腺激素(β-hCG)的标志物来诊断绒癌。我们分析了 62 例原发性和转移性睾丸生殖细胞肿瘤(27 例绒癌、19 例卵黄囊瘤、29 例胚胎癌、28 例精原细胞瘤、22 例畸胎瘤、3 例上皮样滋养细胞肿瘤[ETT])的免疫组织化学表达,包括细胞角蛋白 7(CK7)、抑制素、p63 和β-hCG。所有绒癌和 ETT 均强烈表达 CK7,而精原细胞瘤呈阴性,52%的胚胎癌呈弱阳性。84%的卵黄囊瘤和 59%的畸胎瘤呈 CK7 阳性。89%的绒癌和 100%的 ETT 对抑制素有反应,反应突出合体滋养层,而精原细胞瘤、胚胎癌、卵黄囊瘤和畸胎瘤则无反应。85%的绒癌表达 p63,染色主要位于单核滋养细胞,而精原细胞瘤、胚胎癌和卵黄囊瘤则无反应。32%的畸胎瘤有 p63 表达。96%的绒癌、33%的 ETT、46%的精原细胞瘤、54%的胚胎癌、47%的卵黄囊瘤和 32%的畸胎瘤β-hCG 呈阳性。如果肿瘤中存在其他部位的绒癌,则其他亚型的β-hCG 染色更有可能(P = .0002)。CK7 是绒癌的高度敏感标志物,可将绒癌与精原细胞瘤和胚胎癌区分开来。抑制素和 p63 是绒癌与精原细胞瘤、胚胎癌和卵黄囊瘤的敏感和特异性标志物。为了识别绒癌,CK7、抑制素和 p63 优于β-hCG。